Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multicenter, Open-label, Randomized, 24 Months Follow-up, Two Arm Study to Compare the Efficacy of Everolimus in Improving the Cardiovascular Profile in a Regimen With Mycophenolic Acid vs. a Regimen of CNI+MPA in Maintenance Renal Transplant Recipients.
Brief Summary: The objective of the study is to compare the cardiovascular profile of an everolimus and mycophenolic acid immunosuppressive regimen with a calcineurin inhibitor and mycophenolic acid regimen in maintenance renal transplant patients


Options:
A: Arm Label: Thymoglobulin and everolimus; Type: EXPERIMENTAL; Interventions: Drug: Thymoglobulin, Drug: Everolimus, Drug: Tacrolimus | Arm Label: Basiliximabe and everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Basiliximabe, Drug: Tacrolimus | Arm Label: Basiliximabe and mycophenolate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Basiliximabe, Drug: mycophenolate sodium, Drug: Tacrolimus | Intervention Type: DRUG; Name: Thymoglobulin; Assigned to Arm(s): Thymoglobulin and everolimus | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Basiliximabe and everolimus, Thymoglobulin and everolimus | Intervention Type: DRUG; Name: Basiliximabe; Assigned to Arm(s): Basiliximabe and everolimus, Basiliximabe and mycophenolate | Intervention Type: DRUG; Name: mycophenolate sodium; Assigned to Arm(s): Basiliximabe and mycophenolate | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Thymoglobulin and everolimus | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Basiliximabe and everolimus | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Basiliximabe and mycophenolate
B: Arm Label: Low-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: High-dose Everolimus Group; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Mycophenolic Acid (MPA), Drug: Cyclosporine A (CsA), Drug: Basiliximab, Drug: Corticosteroids | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Mycophenolic Acid (MPA); Assigned to Arm(s): Control Group | Intervention Type: DRUG; Name: Cyclosporine A (CsA); Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Basiliximab; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group | Intervention Type: DRUG; Name: Corticosteroids; Assigned to Arm(s): Control Group, High-dose Everolimus Group, Low-dose Everolimus Group
C: Arm Label: Tacrolimus; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tacrolimus, Drug: Mycophenolic acid (MPA) | Arm Label: Everolimus; Type: EXPERIMENTAL; Interventions: Drug: Everolimus, Drug: Tacrolimus, Drug: Mycophenolic acid (MPA) | Intervention Type: DRUG; Name: Everolimus; Assigned to Arm(s): Everolimus | Intervention Type: DRUG; Name: Tacrolimus; Assigned to Arm(s): Everolimus, Tacrolimus | Intervention Type: DRUG; Name: Mycophenolic acid (MPA); Assigned to Arm(s): Everolimus, Tacrolimus
D: Intervention Type: DRUG; Name: sirolimus; Assigned to Arm(s): N/A

Answer: C